Helicobacter pylori,esophageal precancerous lesions,and proton pump inhibitor overuse  

作　　者：Feng Zhang Hang Zhang Yan-Miao Liu Fu-Shan Tang 

机构地区：[1]Department of Clinical Pharmacy,Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy,Zunyi Medical University,Zunyi 563006,Guizhou Province,China [2]Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education,Zunyi Medical University,Zunyi 563006,Guizhou Province,China [3]The First Clinical Institute,Zunyi Medical University,Zunyi 563006,Guizhou Province,China [4]Key Laboratory of Clinical Pharmacy in Zunyi City,Zunyi Medical University,Zunyi 563006,Guizhou Province,China

出　　处：《World Journal of Gastroenterology》2024年第42期4591-4596,共6页世界胃肠病学杂志（英文）

摘　　要：This article reviews the cohort study published in the World Journal of Gastroenterology,which reported low rates of Helicobacter pylori(H.pylori)infection among esophageal cancer(EC)patients,coupled with proton pump inhibitor(PPI)overuse.These findings suggest a potential protective role of H.pylori against EC and indicate a possible association between PPI use and increased cancer risk.In light of these findings,our article examines the complex relationship between H.pylori and esophageal precancerous lesions,exploring the potential underlying mechanisms.We also address growing concerns regarding PPI overuse,including its potential effects on cancer therapy efficacy and the risk of drug interactions.Ultimately,this article highlights the urgent need for further research to evaluate the safety and efficacy of PPIs in cancer patients and to better understand their broader implications.

关 键 词：Esophageal carcinoma Helicobacter pylori Esophageal precancerous lesions Proton pump inhibitor Drug abuse CANCER 

分 类 号：R735.1[医药卫生—肿瘤]